Symbols / OTLK $0.22 +4.29% Outlook Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
OTLK Chart
About

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 22.91M
Enterprise Value 46.41M Income -102.86M Sales 205.70K
Book/sh -0.60 Cash/sh 0.10 Dividend Yield —
Payout 0.00% Employees 17 IPO —
P/E — Forward P/E -0.80 PEG —
P/S 111.38 P/B -0.37 P/C —
EV/EBITDA -0.79 EV/Sales 225.60 Quick Ratio 0.18
Current Ratio 0.35 Debt/Eq — LT Debt/Eq —
EPS (ttm) -2.89 EPS next Y -0.27 EPS Growth —
Revenue Growth — Earnings 2026-05-14 ROA -209.04%
ROE — ROIC — Gross Margin 0.00%
Oper. Margin 11.16% Profit Margin 0.00% Shs Outstand 104.61M
Shs Float 70.89M Short Float 3.83% Short Ratio 2.73
Short Interest — 52W High 3.39 52W Low 0.16
Beta 0.19 Avg Volume 2.64M Volume 1.47M
Target Price $4.17 Recom Buy Prev Close $0.21
Price $0.22 Change 4.29%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$4.17
Mean price target
2. Current target
$0.22
Latest analyst target
3. DCF / Fair value
$-5.92
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.22
Low
$0.50
High
$6.00
Mean
$4.17

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-11 main Ascendiant Capital Buy → Buy $6
2026-02-18 reit HC Wainwright & Co. Neutral → Neutral $1
2026-02-18 main Chardan Capital Neutral → Neutral $1
2026-01-05 main Chardan Capital Neutral → Neutral $1
2026-01-02 main HC Wainwright & Co. Neutral → Neutral $1
2025-12-22 main Ascendiant Capital Buy → Buy $10
2025-09-30 reit HC Wainwright & Co. Neutral → Neutral $1
2025-09-22 main Ascendiant Capital Buy → Buy $8
2025-08-29 down Guggenheim Buy → Neutral —
2025-08-29 down HC Wainwright & Co. Buy → Neutral $1
2025-08-28 main Chardan Capital Neutral → Neutral $3
2025-08-15 main Chardan Capital Neutral → Neutral $3
2025-06-06 main Ascendiant Capital Buy → Buy $21
2025-02-24 main Ascendiant Capital Buy → Buy $24
2025-02-18 main HC Wainwright & Co. Buy → Buy $3
2025-02-18 main Chardan Capital Neutral → Neutral $3
2025-01-17 reit Guggenheim Buy → Buy $12
2025-01-17 reit HC Wainwright & Co. Buy → Buy $30
2024-12-02 down Chardan Capital Buy → Neutral —
2024-11-29 main BTIG Buy → Buy $9
News
RSS: Latest OTLK news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-05-27 SUKHTIAN GHIATH M Director and Beneficial Owner of more than 10% of a Class of Security — 4,285,714 $1.40 $6,000,000
2025-01-17 SUKHTIAN GHIATH M Director and Beneficial Owner of more than 10% of a Class of Security — 3,458,571 $2.23 $7,712,613
2025-01-17 SUKHTIAN GHIATH M Director and Beneficial Owner of more than 10% of a Class of Security — 3,458,571 $2.51 $8,681,013
2024-09-26 KENYON LAWRENCE A. Chief Financial Officer — 5,000 $5.69 $28,446
2024-04-15 SYNTONE VENTURES, L.L.C. Beneficial Owner of more than 10% of a Class of Security — 714,286 $8.62 $6,157,145
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Total Revenue
1.41
0.00
0.00
0.00
Operating Revenue
1.41
0.00
0.00
0.00
Cost Of Revenue
1.36
0.00
—
—
Reconciled Cost Of Revenue
1.36
0.00
—
—
Gross Profit
0.06
0.00
—
—
Operating Expense
67.12
-6.39%
71.70
+34.97%
53.13
-15.77%
63.07
Research And Development
27.18
-34.92%
41.76
+57.88%
26.45
-37.51%
42.33
Selling General And Administration
39.94
+33.39%
29.94
+12.25%
26.67
+28.61%
20.74
General And Administrative Expense
39.94
+33.39%
29.94
+12.25%
26.67
+28.61%
20.74
Salaries And Wages
16.66
+53.03%
10.89
+21.94%
8.93
-2.14%
9.12
Other Gand A
23.28
+22.18%
19.05
+7.37%
17.75
+52.76%
11.62
Total Expenses
68.48
-4.50%
71.70
+34.97%
53.13
-15.77%
63.07
Operating Income
-67.06
+6.47%
-71.70
-34.97%
-53.13
+15.77%
-63.07
Total Operating Income As Reported
-67.06
+6.47%
-71.70
-34.97%
-53.13
+15.77%
-63.07
EBITDA
-63.58
+11.81%
-72.09
-27.81%
-56.40
+12.36%
-64.36
Normalized EBITDA
-106.59
+3.74%
-110.73
-98.17%
-55.88
+12.41%
-63.80
Reconciled Depreciation
0.12
+2.80%
0.11
+157.67%
0.04
-78.41%
0.20
EBIT
-63.69
+11.79%
-72.21
-27.92%
-56.45
+12.57%
-64.56
Total Unusual Items
43.02
+11.33%
38.64
+7435.32%
-0.53
+5.88%
-0.56
Total Unusual Items Excluding Goodwill
43.02
+11.33%
38.64
+7435.32%
-0.53
+5.88%
-0.56
Special Income Charges
—
0.00
+100.00%
-0.58
+43.67%
-1.03
Other Special Charges
—
—
0.58
-43.67%
1.03
Impairment Of Capital Assets
—
—
—
—
Net Income
-62.42
+17.17%
-75.37
-27.78%
-58.98
+10.70%
-66.05
Pretax Income
-63.98
+15.11%
-75.36
-27.78%
-58.98
+10.70%
-66.05
Net Non Operating Interest Income Expense
-0.19
+91.41%
-2.25
-44.31%
-1.56
-4.86%
-1.49
Interest Expense Non Operating
0.28
-91.03%
3.16
+24.72%
2.53
+70.17%
1.49
Net Interest Income
-0.19
+91.41%
-2.25
-44.31%
-1.56
-4.86%
-1.49
Interest Expense
0.28
-91.03%
3.16
+24.72%
2.53
+70.17%
1.49
Interest Income Non Operating
0.09
-90.10%
0.91
-6.72%
0.97
—
Interest Income
0.09
-90.10%
0.91
-6.72%
0.97
—
Other Income Expense
3.28
+332.53%
-1.41
+67.16%
-4.29
-187.93%
-1.49
Other Non Operating Income Expenses
-39.60
+0.88%
-39.95
-963.56%
-3.76
-325.41%
-0.88
Gain On Sale Of Security
43.02
+11.33%
38.64
+75781.38%
0.05
-89.07%
0.47
Tax Provision
-1.55
-55522.46%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
1.03
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-62.42
+17.17%
-75.37
-27.78%
-58.98
+10.70%
-66.05
Net Income From Continuing Operation Net Minority Interest
-62.42
+17.17%
-75.37
-27.78%
-58.98
+10.70%
-66.05
Net Income From Continuing And Discontinued Operation
-62.42
+17.17%
-75.37
-27.78%
-58.98
+10.70%
-66.05
Net Income Continuous Operations
-62.42
+17.17%
-75.37
-27.78%
-58.98
+10.70%
-66.05
Normalized Income
-104.41
+8.42%
-114.00
-95.03%
-58.46
+10.74%
-65.49
Net Income Common Stockholders
-62.42
+17.17%
-75.37
-27.78%
-58.98
+10.70%
-66.05
Otherunder Preferred Stock Dividend
—
—
—
—
Diluted EPS
-1.79
+55.91%
-4.06
+15.42%
-4.80
+22.58%
-6.20
Basic EPS
-1.79
+55.91%
-4.06
+15.42%
-4.80
+22.58%
-6.20
Basic Average Shares
34.80
+87.59%
18.55
+48.29%
12.51
+17.96%
10.60
Diluted Average Shares
34.80
+87.59%
18.55
+48.29%
12.51
+17.96%
10.60
Diluted NI Availto Com Stockholders
-62.42
+17.17%
-75.37
-27.78%
-58.98
+10.70%
-66.05
Earnings From Equity Interest
-0.14
-39.97%
-0.10
-816.00%
-0.01
+77.43%
-0.05
Line Item Trend 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Total Assets
18.58
-35.52%
28.82
-10.77%
32.30
+13.23%
28.53
Current Assets
17.39
-36.57%
27.42
-11.50%
30.98
+12.57%
27.52
Cash Cash Equivalents And Short Term Investments
8.08
-45.85%
14.93
-36.19%
23.39
+34.46%
17.40
Cash And Cash Equivalents
8.08
-45.85%
14.93
-36.19%
23.39
+34.46%
17.40
Receivables
1.49
0.00
—
—
Accounts Receivable
1.49
0.00
—
—
Inventory
3.34
0.00
—
—
Raw Materials
2.35
—
—
—
Work In Process
0.96
—
—
—
Finished Goods
0.03
—
—
—
Prepaid Assets
—
—
—
10.12
Other Current Assets
4.48
-64.15%
12.49
+64.60%
7.59
-25.05%
10.12
Total Non Current Assets
1.20
-15.06%
1.41
+6.49%
1.32
+31.18%
1.01
Net PPE
0.23
-17.89%
0.27
+949.38%
0.03
-62.80%
0.07
Gross PPE
0.23
-17.89%
0.27
+949.38%
0.03
-62.80%
0.07
Accumulated Depreciation
—
—
—
-1.07
Other Properties
0.23
-17.89%
0.27
+949.38%
0.03
-62.80%
0.07
Investments And Advances
0.55
-20.34%
0.69
-12.69%
0.79
-1.37%
0.80
Long Term Equity Investment
0.55
-20.34%
0.69
-12.69%
0.79
-1.37%
0.80
Other Non Current Assets
0.42
-4.95%
0.44
-12.37%
0.50
+279.73%
0.13
Total Liabilities Net Minority Interest
50.77
-50.17%
101.90
+118.02%
46.74
+136.16%
19.79
Current Liabilities
45.81
+7.66%
42.55
-8.94%
46.73
+136.86%
19.73
Payables And Accrued Expenses
12.78
+6.07%
12.05
+17.48%
10.26
+50.84%
6.80
Payables
10.49
+6.81%
9.83
+16.54%
8.43
+57.65%
5.35
Accounts Payable
10.19
+27.90%
7.97
+21.21%
6.57
+88.30%
3.49
Current Accrued Expenses
2.29
+2.78%
2.22
+21.84%
1.83
+25.77%
1.45
Pensionand Other Post Retirement Benefit Plans Current
3.03
+198.91%
1.01
+10.11%
0.92
-53.45%
1.98
Total Tax Payable
0.30
-83.73%
1.86
+0.00%
1.86
+0.00%
1.86
Income Tax Payable
0.30
-83.73%
1.86
+0.00%
1.86
+0.00%
1.86
Current Debt And Capital Lease Obligation
30.01
+1.75%
29.49
-17.06%
35.56
+224.59%
10.95
Current Debt
29.95
+1.72%
29.44
-17.19%
35.55
+225.71%
10.92
Other Current Borrowings
29.95
+1.72%
29.44
-17.19%
35.55
+225.71%
10.92
Current Capital Lease Obligation
0.06
+15.70%
0.05
+1093.04%
0.00
-88.99%
0.04
Total Non Current Liabilities Net Minority Interest
4.96
-91.65%
59.35
+954168.13%
0.01
-89.87%
0.06
Long Term Debt And Capital Lease Obligation
0.19
-23.54%
0.25
0.00
-100.00%
0.00
Long Term Debt
—
—
—
—
Long Term Capital Lease Obligation
0.19
-23.54%
0.25
0.00
-100.00%
0.00
Stockholders Equity
-32.19
+55.95%
-73.08
-406.15%
-14.44
-265.26%
8.74
Common Stock Equity
-32.19
+55.95%
-73.08
-406.15%
-14.44
-265.26%
8.74
Capital Stock
0.54
+125.42%
0.24
+83.71%
0.13
-94.28%
2.27
Common Stock
0.54
+125.42%
0.24
+83.71%
0.13
-94.28%
2.27
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
53.89
+125.42%
23.91
+83.71%
13.01
+14.49%
11.37
Ordinary Shares Number
53.89
+125.42%
23.91
+83.71%
13.01
+14.49%
11.37
Additional Paid In Capital
572.98
+21.92%
469.97
+3.67%
453.35
+9.14%
415.40
Retained Earnings
-605.71
-11.49%
-543.28
-16.11%
-467.92
-14.42%
-408.94
Total Equity Gross Minority Interest
-32.19
+55.95%
-73.08
-406.15%
-14.44
-265.26%
8.74
Total Capitalization
-32.19
+55.95%
-73.08
-406.15%
-14.44
-265.26%
8.74
Working Capital
-28.43
-87.78%
-15.14
+3.91%
-15.75
-302.20%
7.79
Invested Capital
-2.24
+94.87%
-43.64
-306.68%
21.11
+7.44%
19.65
Total Debt
30.19
+1.54%
29.74
-16.36%
35.56
+224.47%
10.96
Net Debt
21.86
+50.66%
14.51
+19.36%
12.16
—
Capital Lease Obligations
0.25
-16.83%
0.30
+6879.82%
0.00
-90.08%
0.04
Net Tangible Assets
-32.19
+55.95%
-73.08
-406.15%
-14.44
-265.26%
8.74
Tangible Book Value
-32.19
+55.95%
-73.08
-406.15%
-14.44
-265.26%
8.74
Current Notes Payable
—
—
—
—
Derivative Product Liabilities
4.77
-91.93%
59.10
+950197.68%
0.01
-89.12%
0.06
Interest Payable
—
—
—
0.00
Investments In Other Ventures Under Equity Method
—
—
—
—
Investmentsin Joint Venturesat Cost
0.55
-20.34%
0.69
-12.69%
0.79
-1.37%
0.80
Line Item Trend 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Operating Cash Flow
-51.83
+24.66%
-68.79
-60.08%
-42.97
+24.18%
-56.67
Cash Flow From Continuing Operating Activities
-51.83
+24.66%
-68.79
-60.08%
-42.97
+24.18%
-56.67
Net Income From Continuing Operations
-62.42
+17.17%
-75.37
-27.78%
-58.98
+10.70%
-66.05
Depreciation Amortization Depletion
0.12
+2.80%
0.11
+157.67%
0.04
-78.41%
0.20
Depreciation And Amortization
0.12
+2.80%
0.11
+157.67%
0.04
-78.41%
0.20
Other Non Cash Items
33.52
+1149.95%
2.68
+95.58%
1.37
-17.16%
1.66
Stock Based Compensation
8.90
+65.23%
5.39
-2.92%
5.55
-28.06%
7.71
Asset Impairment Charge
—
—
—
—
Operating Gains Losses
-42.87
-3993.89%
-1.05
-294.76%
0.54
-11.61%
0.61
Gain Loss On Investment Securities
-43.02
-3646.93%
-1.15
-2154.62%
-0.05
+89.07%
-0.47
Unrealized Gain Loss On Investment Securities
6.07
+147.22%
2.46
-34.58%
3.76
+325.41%
0.88
Change In Working Capital
4.86
+261.00%
-3.02
-163.49%
4.75
+382.19%
-1.68
Change In Receivables
-1.49
0.00
—
—
Changes In Account Receivables
-1.49
0.00
—
—
Change In Inventory
-3.34
0.00
—
—
Change In Prepaid Assets
8.01
+263.47%
-4.90
-287.29%
2.62
+184.61%
-3.09
Change In Payables And Accrued Expense
1.82
-3.41%
1.89
-20.47%
2.37
+63.40%
1.45
Change In Accrued Expense
1.71
+247.79%
0.49
+169.10%
-0.71
-555.78%
0.16
Change In Payable
0.11
-92.01%
1.39
-54.78%
3.08
+138.05%
1.30
Change In Account Payable
1.67
+19.50%
1.39
-54.78%
3.08
+138.05%
1.30
Change In Other Current Assets
-0.10
-1514.36%
-0.01
+97.17%
-0.21
0.00
Change In Other Current Liabilities
-0.05
-1568.83%
0.00
+112.64%
-0.03
+37.01%
-0.04
Investing Cash Flow
—
—
—
—
Cash Flow From Continuing Investing Activities
—
—
—
—
Net Business Purchase And Sale
—
—
—
—
Purchase Of Business
—
—
—
—
Financing Cash Flow
44.98
-25.43%
60.33
+23.20%
48.97
-17.83%
59.59
Cash Flow From Continuing Financing Activities
44.98
-25.43%
60.33
+23.20%
48.97
-17.83%
59.59
Net Issuance Payments Of Debt
-3.04
-71205.04%
-0.00
-100.02%
19.77
+952.41%
-2.32
Issuance Of Debt
33.10
0.00
-100.00%
30.00
+200.00%
10.00
Repayment Of Debt
-36.14
-846925.69%
-0.00
+99.96%
-10.23
+16.94%
-12.32
Long Term Debt Issuance
33.10
0.00
-100.00%
30.00
+200.00%
10.00
Long Term Debt Payments
-36.14
-846925.69%
-0.00
+99.96%
-10.23
+16.94%
-12.32
Net Long Term Debt Issuance
-3.04
-71205.04%
-0.00
-100.02%
19.77
+952.41%
-2.32
Net Common Stock Issuance
25.40
-57.91%
60.33
+100.95%
30.02
-51.81%
62.31
Proceeds From Stock Option Exercised
22.63
0.00
0.00
-100.00%
0.21
Net Other Financing Charges
—
—
-0.82
-37.32%
-0.60
Changes In Cash
-6.84
+19.14%
-8.46
-241.19%
6.00
+105.35%
2.92
Beginning Cash Position
14.93
-36.19%
23.39
+34.46%
17.40
+20.17%
14.48
End Cash Position
8.08
-45.85%
14.93
-36.19%
23.39
+34.46%
17.40
Free Cash Flow
-51.83
+24.66%
-68.79
-60.08%
-42.97
+24.18%
-56.67
Interest Paid Supplemental Data
0.00
-100.00%
0.47
-59.05%
1.16
-25.48%
1.56
Change In Income Tax Payable
-1.55
0.00
—
—
Change In Tax Payable
-1.55
0.00
—
—
Common Stock Issuance
25.40
-57.91%
60.33
+100.95%
30.02
-51.81%
62.31
Earnings Losses From Equity Investments
0.14
+39.97%
0.10
+816.00%
0.01
-77.43%
0.05
Issuance Of Capital Stock
25.40
-57.91%
60.33
+100.95%
30.02
-51.81%
62.31
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category